Friday, January 27, 2012
Auxilium Pharmaceuticals Inc., of Malvern, Pa., initiated a Phase Ib trial of Xiaflex (collagenase clostridium histolyticum) for edematous fibrosclerotic panniculopathy, or cellulite. Xiaflex, a collagenase mixture that breaks down collagen, is approved for Dupuytren's contracture and would work similarly in cellulite to release the collagen tethers that cause skin dimpling.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.